The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...

Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...

The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen ...

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient ...

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in ...